Skip to main content

Table 5 Mean mSASSS variations and respective 95% CIs calculated using a normal approximation (except for certolizumab pegol, whose 95% CI was reported by the authors of the original study). Data from different studies were pooled when the same outcomes from the same treatments were available and when they referred to doses and/or regimens approved in Brazil

From: The Brazilian Society of Rheumatology guidelines for axial spondyloarthritis – 2019

OutcomemSASSS variation (units)
Follow-up time (years)
0 to 20 to 4
DrugΔ mSASSS95% CIΔ mSASSS95% CI
Infliximab [171, 172]0.90.54–1.261.601.1–2.1
Etanercept [173]0.910.62–1.21  
Adalimumab [174]0.90.51–1.09  
Golimumab [175]0.90.38–1.401.300.9–1.7
Certolizumab pegol [176]0.670.21–1.130.980.34–1.63
Secukinumab [145, 177]0.50.11–0.891.20.29–2.11